Brand Intelligence Graphcompany
Company Overview
About Hologic
Hologic is a global medical technology company uniquely dedicated to women's health, founded in 1985 and headquartered in Marlborough, Massachusetts, trading on Nasdaq (HOLX). The company generated approximately $3.9 billion in revenues for fiscal year 2024 (ending September 28) under CEO Stephen MacMillan, who has led Hologic since 2013 and transformed it from a single-product mammography company into a diversified women's health platform. Hologic's four business segments serve distinct clinical needs: Diagnostics (Panther molecular testing platform, cervical health testing, and COVID-19 diagnostics), Breast Health (3D mammography, breast biopsy guidance systems, radiation therapy), Surgical (NovaSure endometrial ablation, MyoSure fibroid removal, and minimally invasive hysteroscopy), and Skeletal Health (bone density measurement).
Business Model & Competitive Advantage
The 3D Genius Mammography system—based on tomosynthesis technology that creates a 3D X-ray view of breast tissue, dramatically improving cancer detection versus traditional 2D mammography—is Hologic's foundational product and the standard of care for breast cancer screening at the majority of U.S. mammography facilities. The Panther system, inherited through Hologic's 2012 acquisition of Gen-Probe for $3.7 billion, is the leading fully automated molecular diagnostics platform for sexually transmitted infections (chlamydia, gonorrhea, trichomonas, HPV), enabling high-throughput testing in clinical labs. The COVID pandemic temporarily transformed Hologic into a major diagnostics company as Panther's throughput capacity enabled COVID-19 molecular test production, generating $1+ billion in quarterly COVID test revenues in 2021-2022 before declining to baseline.
Competitive Landscape 2025–2026
In 2025-2026, Hologic navigates the post-COVID revenue normalization while reinvesting COVID windfall profits into acquisitions and R&D that expand the women's health platform. Acquisitions of Bolder Surgical (2021), Mobidiag (molecular diagnostics), and Acessa Health (laparoscopic fibroid treatment) have expanded the minimally invasive surgical portfolio and international diagnostics presence. The Breast Health business benefits from expanded mammography screening guidelines recommending annual screening beginning at age 40 (updated American Cancer Society and USPSTF guidance), which increases the addressable screening population by approximately 30%. Competitors include Becton Dickinson (molecular diagnostics), Siemens Healthineers and GE HealthCare (imaging), and Cooper Surgical (minimally invasive gynecological procedures).
The Hologic Story
Founders
Recent Activity
View all →Company Timeline
Major milestones in Hologic's journey
Leadership Team
Meet the leaders behind Hologic
Stephen P. MacMillan
Stephen MacMillan has served as Chairman, President and CEO of Hologic since joining the company in December 2013, with his election as Chairman in June 2015. He holds a B.A. in Economics from Davidson College and is a graduate of Harvard Business School's Advanced Management Program. MacMillan previously served as CEO of Stryker Corporation (2005-2011), where he tripled revenue from $2.8 billion to $8.3 billion, and held senior executive roles at Pharmacia Corporation, Johnson & Johnson, and Procter and Gamble. He currently serves as independent director and non-executive chair of Illumina, Inc.
Essex D. Mitchell
Essex Mitchell has served as Chief Operating Officer of Hologic since 2024, overseeing the company's global operations across all business segments including Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. He is responsible for operational excellence, supply chain management, and manufacturing strategy across Hologic's global footprint.
Karleen M. Oberton
Karleen Oberton serves as Chief Financial Officer of Hologic, leading the company's global financial operations, strategic planning, investor relations, and corporate development initiatives. She oversees financial reporting, capital allocation, and played a key role in Hologic's fiscal 2024 financial performance with $4.03 billion in revenue and strong cash flow generation.
Paul Malenchini
Paul Malenchini has served as Chief Information Officer of Hologic since 2021, leading the company's global technology strategy, digital transformation initiatives, and information systems infrastructure. He oversees IT operations supporting Hologic's research and development, manufacturing, and commercial operations across 36+ countries.
Anne Liddy
Anne Liddy serves as General Counsel for Hologic, overseeing all legal affairs, regulatory compliance, corporate governance, and risk management. She provides legal leadership for the company's strategic acquisitions including the Endomagnetics and Gynesonics transactions, and manages intellectual property protection for Hologic's extensive patent portfolio.
Alana Dros
Alana Dros leads Hologic's human resources organization as Vice President, overseeing talent acquisition, employee development, compensation and benefits, and workplace culture initiatives. Under her leadership, Hologic has achieved 90% employee satisfaction ratings and received the Gallup Exceptional Workplace Award for three consecutive years.
Key Differentiators
Market Leader
Hologic is recognized as a market leader in the Healthcare Tech sector, demonstrating strong industry presence and customer trust.
Enterprise Scale
With $3.9B in revenue, Hologic operates at enterprise scale with proven market validation.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu
GE HealthCare
GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designin
Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation,
Biogen
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and com
Danaher Corporation
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, man
Revvity
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid
Compare Hologic with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Hologic? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Hologic Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Hologic vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →